The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency
Article first published online: 12 MAR 2008
British Journal of Haematology
Volume 84, Issue 3, pages 464–470, July 1993
How to Cite
Garcia-Suarez, J., Prieto, A., Reyes, E., Manzano, E., Merino, J. L. and Alvarez-Mon, M. (1993), The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency. British Journal of Haematology, 84: 464–470. doi: 10.1111/j.1365-2141.1993.tb03102.x
- Issue published online: 12 MAR 2008
- Article first published online: 12 MAR 2008
- Received 10 August 1992; accepted for publication 1 March 1993
Summary. In this work we have furthered the understanding of the alterations of T lymphocytes from 29 patients with active autoimmune thrombocytopenic purpura (ATP) and the clinical significance of their lymphocytes. An increased percentage of in vivo activated (CD25+ and DR+) T lymphocytes was found in ATP patients with respect to that found in 22 healthy controls. The function of these T cells measured as the proliferative response to polyclonal mitogenic signals is heterogeneously impaired in ATP patients. T lymphocytes from 65·5% (19/29) of the ATP patients showed a decreased proliferative response to these mitogenic signals. This functional alteration is associated with a redistribution of the T cell compartment in these patients' peripheral blood since a significant decrease of CD4+ T lymphocytes was found.
We have also found that the impairment of the T cell function is different in the diverse clinical situations of the disease. Those with stable, untreated disease showed a marked decrease in the T cell proliferative response to mitogens. Furthermore, those patients who did not respond either to steroids or to splenectomy showed significantly reduced T lymphocyte blastogenesis after phytohaemagglutinin (PHA) stimulation in comparison to that found in responding patients.